Skip to main content
Top

2021 | OriginalPaper | Hoofdstuk

4. Urologische tumoren

Auteurs : M. C. C. M. Hulshof, MD, PhD, J. H. Brondijk, BSc, A. Holtmaat, MSc

Gepubliceerd in: Radiotherapie bij de oncologische patiënt

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Inhoud – 1 Inleiding – 2 Prostaat – 3 Blaas – 4 Testis – 5 Penis – Tumoren van het urogenitaalstelsel vormen een belangrijke groep binnen de radiotherapie. Bij jonge mannen staan de maligne testistumoren op de voorgrond, terwijl op oudere leeftijd het prostaatcarcinoom de meest voorkomende maligniteit is. Het spierinvasieve blaascarcinoom is een relatief minder vaak voorkomende tumor, maar agressiever in gedrag. Deze drie tumoren zullen in dit hoofdstuk worden beschreven. Prostaat- en blaascarcinoom zijn belangrijk voor de radiotherapie gezien de vergelijkbare uitkomsten met die van een operatie en de hoge leeftijd waarop ze vaak gediagnosticeerd worden, waardoor chirurgie niet mogelijk is. Het peniscarcinoom is relatief zeldzaam, en zal slechts kort worden behandeld. Andere urologische tumoren, waarbij bestraling alleen op specifieke indicaties een rol speelt (zoals het niercelcarcinoom), zullen hier niet aan de orde komen.
Literatuur
1.
go back to reference Vis AN, Jansen B, Oprea-Lager DE. PSMA-PET/CT-imaging bij de diagnostiek van prostaatkanker. Tijdschr Urol. 2018;8(1):10–7.CrossRef Vis AN, Jansen B, Oprea-Lager DE. PSMA-PET/CT-imaging bij de diagnostiek van prostaatkanker. Tijdschr Urol. 2018;8(1):10–7.CrossRef
2.
go back to reference Moon DH, Efstathiou JA, Chen RC. What is the best way to radiate the prostate in 2016? Urol Oncol. 2016;35(2):59–68.CrossRef Moon DH, Efstathiou JA, Chen RC. What is the best way to radiate the prostate in 2016? Urol Oncol. 2016;35(2):59–68.CrossRef
3.
go back to reference Bolla M, Descotes JL, Artignan X, Fourneret P. Adjuvant treatment to radiation: combid hormone therapy and external radiotherapy for locally advanced prostate cancer. BJU Int. 2007;100(suppl 2):44–78.CrossRef Bolla M, Descotes JL, Artignan X, Fourneret P. Adjuvant treatment to radiation: combid hormone therapy and external radiotherapy for locally advanced prostate cancer. BJU Int. 2007;100(suppl 2):44–78.CrossRef
4.
go back to reference de Ru VJ, Scheurleer JS, Welleweerd J, editors. Radiobiologie en stralingsbescherming. 6e Serie: Medische Beeldvorming en Radiotherapie. Houten: Bohn Stafleu van Loghum; 2016. de Ru VJ, Scheurleer JS, Welleweerd J, editors. Radiobiologie en stralingsbescherming. 6e Serie: Medische Beeldvorming en Radiotherapie. Houten: Bohn Stafleu van Loghum; 2016.
5.
go back to reference Coia L, Emami B, Solin LJ, Munzenrider JE, Lyman J, Shank B, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.CrossRef Coia L, Emami B, Solin LJ, Munzenrider JE, Lyman J, Shank B, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.CrossRef
6.
go back to reference McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, et al. MRI-guided prostate adaptive radiotherapy: a systematic review. Radiother Oncol. 2016;119(3):371–80.CrossRef McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, et al. MRI-guided prostate adaptive radiotherapy: a systematic review. Radiother Oncol. 2016;119(3):371–80.CrossRef
8.
go back to reference Pinitpatcharalert A, Happersett L, Kollmeier M, McBride S, Gorovets D, Tyagi N, et al. Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer. Adv Radiat Oncol. 2019;4(2):337–44. https://doi.org/10.1016/j.adro.2018.12.001. Pinitpatcharalert A, Happersett L, Kollmeier M, McBride S, Gorovets D, Tyagi N, et al. Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer. Adv Radiat Oncol. 2019;4(2):337–44. https://​doi.​org/​10.​1016/​j.​adro.​2018.​12.​001.
9.
go back to reference De Vries KC, Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. 2010;106(1):108–15. https://doi.org/10.1016/j.ijrobp.2019.09.007. De Vries KC, Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. 2010;106(1):108–15. https://​doi.​org/​10.​1016/​j.​ijrobp.​2019.​09.​007.
13.
go back to reference Bruynzeel AME, Tetar SU, Oei SS, Senan S, Haasbeek CJA, Spoelstra FOB, et al. A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results. Int J Radiat Oncol Biol Phys. 2019;105(5):1086–94.CrossRef Bruynzeel AME, Tetar SU, Oei SS, Senan S, Haasbeek CJA, Spoelstra FOB, et al. A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results. Int J Radiat Oncol Biol Phys. 2019;105(5):1086–94.CrossRef
14.
go back to reference Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, LucaIncrocci MD. Moderate hypofractionation in intermediate- and high-risk, localized prostate cancer: health-related quality of life from the randomized, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. 2019;103(4):823–33. https://doi.org/10.1016/j.ijrobp.2018.11.020. Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, LucaIncrocci MD. Moderate hypofractionation in intermediate- and high-risk, localized prostate cancer: health-related quality of life from the randomized, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. 2019;103(4):823–33. https://​doi.​org/​10.​1016/​j.​ijrobp.​2018.​11.​020.
15.
go back to reference Arcangeli G, Strigari L, Arcangeli S. Radical cystectomy versus organ sparing trimodality treatment in muscle invasive bladder cancer: a systematic review of clinical trials. Crit Rev Oncol Hematol. 2015;95(3):387–96.CrossRef Arcangeli G, Strigari L, Arcangeli S. Radical cystectomy versus organ sparing trimodality treatment in muscle invasive bladder cancer: a systematic review of clinical trials. Crit Rev Oncol Hematol. 2015;95(3):387–96.CrossRef
16.
go back to reference Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. Clin Oncol. 2017;35(20):2299–305. https://doi.org/10.1200/JCO.2016.69.2327. Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. Clin Oncol. 2017;35(20):2299–305. https://​doi.​org/​10.​1200/​JCO.​2016.​69.​2327.
17.
go back to reference Calabrò F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2009;55(2):348–58.CrossRef Calabrò F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2009;55(2):348–58.CrossRef
18.
go back to reference Froma A, Mast M, Welleweerd H, editors. Techniek in de radiotherapie. Houten: Bohn Stafleu van Loghum; 2020. Froma A, Mast M, Welleweerd H, editors. Techniek in de radiotherapie. Houten: Bohn Stafleu van Loghum; 2020.
20.
go back to reference Beulens AJW, Van der Toorn PP, De Wildt MJ, Scheepens WA. High-precision bladder cancer irradiation in the elderly: clinical results for a plan-of-the-day integrated boost technique with image guidance using lipiodol markers. Euro Urol Oncol. 2019;2(1):39–46. https://doi.org/10.1016/j.euo.2018.08.012. Beulens AJW, Van der Toorn PP, De Wildt MJ, Scheepens WA. High-precision bladder cancer irradiation in the elderly: clinical results for a plan-of-the-day integrated boost technique with image guidance using lipiodol markers. Euro Urol Oncol. 2019;2(1):39–46. https://​doi.​org/​10.​1016/​j.​euo.​2018.​08.​012.
21.
go back to reference Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27(7):1299–304. https://doi.org/10.1093/annonc/mdw164. Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27(7):1299–304. https://​doi.​org/​10.​1093/​annonc/​mdw164.
Metagegevens
Titel
Urologische tumoren
Auteurs
M. C. C. M. Hulshof, MD, PhD
J. H. Brondijk, BSc
A. Holtmaat, MSc
Copyright
2021
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/16013_2020_18